Fact or fiction: What do the benign prostatic hyperplasia data tell us?

Current Urology Reports

Volumn 6, Issue 4, 2005, Pages 243-250

  Shabbir, Majid ^b   Kirby, Roger S ^a  

^a London Clinic Cancer Centre   (United Kingdom)

^b NONE

Author keywords

Benign Prostatic Hyperplasia; Finasteride; International Prostate Symptom Score; Lower Urinary Tract Symptom; Tamsulosin

Indexed keywords

ALGORITHM; ANIMAL; CATHETER ABLATION; DISEASE COURSE; HUMAN; LASER COAGULATION; MALE; PATHOPHYSIOLOGY; PROSTATE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RAT; REVIEW; STENT; TRANSURETHRAL RESECTION; URINE RETENTION; URODYNAMICS;

ALGORITHMS; ANIMALS; CATHETER ABLATION; DISEASE PROGRESSION; HUMANS; LASER COAGULATION; MALE; PROSTATE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; RATS; STENTS; TRANSURETHRAL RESECTION OF PROSTATE; URINARY RETENTION; URODYNAMICS;

EID: 27744584735     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-005-0016-3     Document Type: Article

References (48)

1. McConnell JD, Barry MJ, Bruskewitz RC, et al.: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline, no 8. Rockville, MD: Agency for Health Care Policy and Research, US Public Health Service, US Dept. of Health and Human Services; 1994. AHCAR Publication No. 94-0582.
2. Anderson JB, Roehrborn CG, Schalken JA, et al.: The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 2001, 39:390–399. DOI: 10.1159/000052475
3. Berry SJ, Coffey DS, Walsh PC, et al.: The development of human BPH with age. J Urol 1984, 132:474–479.
4. Arrighi H, Guess H, Metter E, Fozard J: Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 1990, 16:253–261. DOI: 10.1002/pros.2990160309
5. Drach GW, Layton TN, Binard WJ: Male peak urinary flow: relationship of voided volume and age. J Urol 1979, 122:210–214.
6. Levin RM, Chichester P, Hass MA, et al.: Obstructive bladder dysfunction: morphological, biochemical, and molecular changes. Eur Urol 2002, 9(suppl 1):14–20.
7. Tubaro A, Carter S, Hind A, et al.: A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with BPH. J Urol 2001, 166:172–176. DOI: 10.1016/S0022-5347(05)66102-2
8. Kojima M, Inui E, Ochii A, et al.: Reversible change in bladder hypertrophy due to BPH after surgical relief of obstruction. J Urol 1997, 158:89–93. DOI: 10.1097/00005392-199707000-00024
9. Sironi D, Levorato C, Deiana G, et al.: Decrease of ultrasoundestimated bladder weight during tamsulosin treatment in patients with benign prostatic enlargement. Arch Ital Urol Androl 2002, 74:90–94.
10. Djavan B, Marberger M: A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999, 36:1–13. DOI: 10.1159/000019919
11. Shabbir M, Mikhailidis DM, Morgan RJ: Erectile dysfunction: an underdiagnosed condition associated with multiple risk factors. Curr Med Res Opin 2004, 20:603–606. DOI: 10.1185/030079904125003458
12. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE: Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974, 186:1213–1215. DOI: 10.1126/science.186.4170.1213
13. Steers WD: 5 alpha-reductase activity in the prostate. Urology 2001, 58(suppl 1):17–24. DOI: 10.1016/S0090-4295(01)01299-7
14. McConnell JD, Bruskewitz R, Walsh P, et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998, 338:557–563. DOI: 10.1056/NEJM199802263380901
15. Schafer W, Tammela TL, Barrett DM, et al.: Continued improvement in pressure-flow parameters in men receiving finasteride for 2 years. Finasteride Urodynamics Study Group. Urology 1999, 54:278–283. DOI: 10.1016/S0090-4295(99)00130-2
16. Roehrborn CG, Boyle P, Bergner D, et al.: Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a 4-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999, 54:662–669. DOI: 10.1016/S0090-4295(99)00232-0
17. Andriole G, Bruchovsky N, Chung LW: Dihydrotestosterone and the prostate: the scientific rationale for 5 alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004, 172:1399–1403. DOI: 10.1097/01.ju.0000139539.94828.29
18. McConnell JD, Roehrborn CG, Bautista OM, et al.: The longterm effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387–2398. Landmark trial that compared the effects of treating BPH with doxazosin, finasteride, or combination therapy in more than 3000 men. Combination therapy was more effective than monotherapy with finasteride or doxazosin for preventing disease progression in BPH. DOI: 10.1056/NEJMoa030656
19. Speakman MJ, Kirby RS, Joyce A, et al.: Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004, 93:985–990. DOI: 10.1111/j.1464-410X.2004.04765.x
20. Wasson JH, Reda DJ, Bruskewitz RC, et al.: A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995, 332:75–79. DOI: 10.1056/NEJM199501123320202
21. Roos NP, Wennberg JE, Malenka DJ: Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med 1989, 320:1120–1124. DOI: 10.1056/NEJM198904273201705
22. Yang Q, Peters TJ, Donovan JL, et al.: Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and metaanalysis of randomized, controlled trials. J Urol 2001, 165:1526–1532. DOI: 10.1016/S0022-5347(05)66342-2
23. Christensen MM, Aagaard J, Madsen PO: Transurethral resection versus transurethral incision of the prostate: a prospective, randomized study. Urol Clin North Am 1990, 17:621–630.
24. Riehmann M, Bruskewitz R: Transurethral incision of the prostate and bladder neck. J Androl 1991, 12:415–422.
25. Riehmann M, Knes JM, Heisey D, et al.: Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 1995, 45:768–775. DOI: 10.1016/S0090-4295(99)80081-8
26. Janknegt RA: Surgical management for benign prostatic hyperplasia: indications, techniques, and results. Prostate Suppl 1989, 2:79–93. DOI: 10.1002/pros.2990150509
27. Milroy E, Chapple CR: The UroLume stent in the management of benign prostatic hyperplasia. J Urol 1993, 150:1630–1635.
28. Oesterling JE, Kaplan SA, Epstein HB, et al.: The North American experience with the UroLume endoprosthesis as a treatment for benign prostatic hyperplasia: long-term results. The North American UroLume Study Group. Urology 1994, 44:353–362. DOI: 10.1016/S0090-4295(94)80093-6
29. Masood S, Djaladat H, Kouriefs C, et al.: The 12-year outcome analysis of an endourethral wallstent for treating benign prostatic hyperplasia. BJU Int 2004, 94:1271–1274. DOI: 10.1111/j.1464-410X.2004.05155.x
30. Gottfried HW, Schimers HP, Gschwend J, et al.: Initial experiences with the Memotherm Stent in treatment of benign prostatic hyperplasia. Urologe A 1995, 34:110–118.
31. Gesenberg A, Sintermann R: Management of benign prostatic hyperplasia in high risk patients: long-term experience with the Memotherm stent. J Urol 1998, 160:72–76. DOI: 10.1016/S0022-5347(01)63034-9
32. Zlotta AR, Raviv G, Peny MO, et al.: Possible mechanisms of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: a neurohistochemical study. J Urol 1997, 157:894–899. DOI: 10.1016/S0022-5347(01)65077-8
33. Naslund MJ: Transurethral needle ablation of the prostate. Urology 1997, 50:167. DOI: 10.1016/S0090-4295(97)00277-X
34. Roehrborn CG, Issa MM, Bruskewitz RC, et al.: Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study. Urology 1998, 51:415–421. DOI: 10.1016/S0090-4295(97)00682-1
35. Zlotta AR, Giannakopoulos X, Maehlum O, et al.: Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to 5 years from three centers. Eur Urol 2003, 44:89–93. DOI: 10.1016/S0302-2838(03)00218-5
36. Hill B, Belville W, Bruskewitz R, et al.: Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004, 171:2336–2340. A large, multicenter, randomized study comparing the long-term effects of TUNA versus TURP (5-year follow-up data presented). No significant difference was found between the two treatments with regard to improvements in mean symptom score or quality of life, but significant differences were seen in Qmax and PVR. However, patients undergoing TURP experienced a greater number of adverse events compared with those undergoing TUNA. DOI: 10.1097/01.ju.0000127761.87421.a0
37. Steele GS, Sleep DJ: Transurethral needle ablation of the prostate: a urodynamic based study with 2-year follow-up. J Urol 1997, 158:1834–1838. DOI: 10.1016/S0022-5347(01)64140-5
38. Floratos DL, Kiemeney LA, Rossi C, et al.: Long-term follow-up of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. J Urol 2001, 165:1533–1538. DOI: 10.1016/S0022-5347(05)66343-4
39. de Wildt MJ, Debruyne FM, de la Rosette JJ: High-energy transurethral microwave thermotherapy: a thermoablative treatment for benign prostatic obstruction. Urology 1996, 48:416–423. DOI: 10.1016/S0090-4295(96)00189-6
40. Arai Y, Aoki Y, Okubo K, et al.: Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study. J Urol 2000, 164:1206–1211. DOI: 10.1016/S0022-5347(05)67142-X
41. FDA/Centre for Devices and Radiological Health: FDA Public Health Notification: Serious Injuries from Microwave Thermotherapy for Benign Prostatic Hyperplasia. US Food and Drug Administration, 2000. http://www.fda/ogv/cdrh/ saftey.bph.html. Accessed January 2004.
42. Gilling PJ, Cass CB, Malcolm AR, Fraundorfer MR: Combination holmium and Nd:YAG laser ablation of the prostate: initial clinical experience. J Endourol 1995, 9:151–153. DOI: 10.1089/end.1995.9.151
43. Tan AH, Gilling PJ, Kennett KM, et al.: Long-term results of high-power holmium laser vaporization (ablation) of the prostate. BJU Int 2003, 92:707–709. DOI: 10.1046/j.1464-410X.2003.04474.x
44. Mottet N, Anidjar M, Bourdon O, et al.: Randomized comparison of transurethral electroresection and holmium: YAG laser vaporization for symptomatic benign prostatic hyperplasia. J Endourol 1999, 13:127–130.
45. A, WesterbergGilling PJ, Kennett K, et al.: Holmium laser resection of the prostate versus transurethral resection of the prostate: results of a randomized trial with 4-year minimum long-term follow-up. J Urol 2004, 172:616–619. A 4-year follow-up study comparing TURP and HoLRP showed a comparable long-term improvement in mean symptom score and Qmax in both treatment groups. In the HoLRP group, none of the patients required blood transfusion (TURP transfusion rate, 6.7%). There were no significant differences between the two groups with regard to urethral stricture development, potency, or retrograde ejaculation. However, the mean catheter time and the mean hospital stay were significantly shorter in the holmium versus the TURP group.
46. Tan AH, Gilling PJ, Kennett KM, et al.: A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol 2003, 170:1270–1274. Study comparing HoLEP with TURP in large prostate glands. It was found that both procedures were equally effective at improving symptom scores and Qmax, with no significant difference noted between the two procedures at 12 months. HoLEP with tissue morcellation took almost twice as long to perform, although more prostate tissue was resected (40.4 vs 24.7 G). HoLEP had a shorter mean catheter time and hospital stay and a lower total complication rate. HoLEP also resulted in a more substantial urodynamic improvement after 6 months, although this likely was a result of the greater tissue resection used. DOI: 10.1097/01.ju.0000086948.55973.00
47. Kuntz RM, Lehrich K: Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm: a randomized, prospective trial of 120 patients. J Urol 2002, 168:1465–1469. First prospective, randomized, controlled trial comparing HoLEP with open prostatectomy in patients with prostates larger than 100 G. Both treatments were equally effective at improving bladder outflow obstruction at 6 months. Although HoLEP had a greater operative time, it had a shorter mean catheter time and hospital stay. Both treatments had a similar complication rate, although 13% of patients undergoing open surgery required transfusion compared with none after HoLEP. DOI: 10.1016/S0022-5347(05)64475-8
48. Fraundorfer MR, Gilling PJ, Kennett KM, Dunton NG: Holmium laser resection of the prostate is more cost effective than transurethral resection of the prostate: results of a randomized, prospective study. Urology 2001, 57:454–458. DOI: 10.1016/S0090-4295(00)00987-0